Abstract:Background and Purpose Nitazoxanide is a clinic anthelmintic drug. Our previous studies found that nitazoxanide and its metabolite tizoxanide activated AMPK and inhibited STAT3 signals. Since AMPK activation and/or STAT3 inhibition are approaches for treating pulmonary fibrosis, we hypothesized that nitazoxanide would be therapeutic for experimental pulmonary fibrosis. Experimental Approach The mitochondrial oxygen consumption rate of cells was measured by using the high‐resolution respirometry system Oxygraph‐2K. The mitochondrial membrane potential of cells was evaluated by tetramethyl rhodamine methyl ester (TMRM) staining. The target protein levels were measured by using western blotting technique. The mice pulmonary fibrosis model was established through intratracheal instillation of bleomycin and the pathological examination of lung tissues was performed by using Hematoxylin and eosin (H&E) and Masson staining. Key Results Nitazoxanide and tizoxanide activated AMPK and inhibited STAT3 signaling in human lung fibroblast cells (MRC‐5 cells). Nitazoxanide and tizoxanide inhibited TGF‐β1‐induced proliferation and migration of MRC‐5 cells, inhibited collagen‐I and α‐SMA expression and inhibited collagen‐I secretion from MRC‐5 cells. Nitazoxanide and tizoxanide inhibited epithelial‐mesenchymal transition (EMT) and inhibited TGF‐β1‐induced smad2/3 activation in mouse lung epithelial cells (MLE‐12 cells). Oral administration of nitazoxanide improved the bleomycin‐induced mice pulmonary fibrosis, and in the established bleomycin‐induced mice pulmonary fibrosis, delayed nitazoxanide treatment attenuated the fibrosis progression. Conclusion and Implications Nitazoxanide improves the bleomycin‐induced pulmonary fibrosis in mice, suggesting a potential application of nitazoxanide for pulmonary fibrosis treatment in clinic.

Anthelmintics nitazoxanide protects against experimental pulmonary fibrosis